Bioinformatics-based potential therapeutic approach against COVID-19
Widespread media coverage of SARS-CoV-2 research results presented by Jun.-Prof. Andreas and Alina Renz
An alveolar macrophage infected by the coronavirus is forced to produce new virus particles
Proliferation of the COVID-19 virus is only possible through reprogramming the metabolism of its human host and exploiting their enzymes. With the help of a detailed computer model by the Computational Systems Biology of Infection group of Jun.-Prof. Andreas Dräger it is now possible to identify the human enzyme which is ncessary for COVID-19 virus proliferation, but whose function is not essential for cell preservation. Thus this enzyme may be a suitable target for an antiviral agent. The results of this study have been published in the current issue of the Bioinformatics journal (FBA reveals guanylate kinase as a potential target for antiviral therapies against SARS-CoV-2).
In cooperation with the Fraunhofer Institute for Molecular Biology and Applied Ecology IME in Hamburg, scientists are now investigating whether medical treatment targeting this enzyme will inhibit coronavirus proliferation.